ProPhase Labs (NASDAQ:PRPH) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

ProPhase Labs (NASDAQ:PRPH) released its earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05), FiscalAI reports. The company had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $5.69 million.

ProPhase Labs Price Performance

PRPH traded down $0.02 during midday trading on Wednesday, reaching $0.23. 1,518,809 shares of the company’s stock were exchanged, compared to its average volume of 5,464,523. ProPhase Labs has a one year low of $0.22 and a one year high of $0.93. The firm has a market capitalization of $9.70 million, a price-to-earnings ratio of -0.40 and a beta of -0.28. The business has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.38. The company has a quick ratio of 0.93, a current ratio of 0.96 and a debt-to-equity ratio of 0.20.

Wall Street Analysts Forecast Growth

PRPH has been the subject of a number of research analyst reports. Wall Street Zen raised shares of ProPhase Labs to a “hold” rating in a research report on Saturday, September 13th. Weiss Ratings restated a “sell (e+)” rating on shares of ProPhase Labs in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, ProPhase Labs currently has an average rating of “Sell”.

Institutional Trading of ProPhase Labs

A hedge fund recently bought a new stake in ProPhase Labs stock. XTX Topco Ltd acquired a new position in shares of ProPhase Labs, Inc. (NASDAQ:PRPH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 102,506 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned approximately 0.25% of ProPhase Labs at the end of the most recent reporting period. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.